Melanoma symptoms provide key warning signs that can help you find this disease early, when it is most treatable. Learn ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following CD19-directed CAR-T, according to results of a phase 1 study.More than 80% ...

New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...

The field of cellular immunotherapy has undergone a profound transformation in recent years, with autologous chimeric antigen receptor (CAR) T-cell therapies emerging as the standard-of-care option ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...

Treatment of Cutaneous T-Cell Lymphoma/Mycosis Fungoides Sareeta R.S. Parker; Bridget Bradley Disclosures Dermatology Nursing. 2006;18 (6):566-575. 0 ...

Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ...

A Phase 1 study for C-CAR039 was conducted in China for the treatment of patients with B-cell non-Hodgkin lymphoma (predominantly LBCL).3 Johnson & Johnson is also evaluating the safety and ...

A study of (neo)adjuvant V940 and pembrolizumab in cutaneous squamous cell carcinoma (V940-007). ClinicalTrials.gov. Updated January 29, 2025.

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukaemia (B-ALL), the commonest cancer in childhood and one that can be ...